Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

NCT01516970 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG: Darunavir/Ritonavir (DRV/r)
DRUG: Lopinavir in fixed combination with Ritonavir
DRUG: Zidovudine
DRUG: NRTIs
DRUG: Efavirenz

Sponsor

Janssen-Cilag G.m.b.H